OncoMatch/Clinical Trials/NCT05894018
Brachytherapy (Iodine-125 Seeds) and Fluzoparib Combination Therapy for Advanced Unresectable Soft Tissue Sarcoma
Is NCT05894018 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Fluzoparib for sarcoma,soft tissue.
Treatment: Fluzoparib — To evaluate the effectiveness and safety of radioactive particles in combination with the PARP inhibitor fluzoparib in the treatment of advanced inoperable soft tissue sarcoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Sarcoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy (doxorubicin, ifosfamide) — first-line
Received systemic therapy (such as standard treatment: doxorubicin plus ifosfamide) ± surgical resection as the first-line treatment
Cannot have received: chemotherapy, surgery
Exception: less than 4 weeks after completion of treatment (last dose) and prior to study dosing; or patients who have not recovered from adverse events (other than alopecia) caused by prior treatment to ≤ CTCAE grade 1
Patients who have received prior chemotherapy, surgery, less than 4 weeks after completion of treatment (last dose) and prior to study dosing; or patients who have not recovered from adverse events (other than alopecia) caused by prior treatment to ≤ CTCAE grade 1
Cannot have received: external radiotherapy
Prior external radiotherapy to the lesion
Lab requirements
Blood counts
Absolute neutrophil count ≥1.5×10^9/L; Platelets ≥80×10^9/L; Hemoglobin ≥90 g/L
Kidney function
Serum creatinine ≤1.5×ULN
Liver function
Bilirubin ≤1.5×ULN; ALT and AST ≤3×ULN; Alkaline phosphatase (AKP) ≤2.5×ULN
Cardiac function
No NYHA class 2 or higher heart failure, unstable angina, myocardial infarction within 1 year, clinically significant arrhythmias requiring treatment or intervention, QTc>450ms (men), QTc>470ms (women)
Normal function of important organs, including: Absolute neutrophil count ≥1.5×10^9/L; Platelets ≥80×10^9/L; Hemoglobin ≥90 g/L; Serum albumin ≥28 g/L; Thyroid-stimulating hormone (TSH) ≤1×ULN (if abnormal, FT3 and FT4 levels should be examined simultaneously, and if FT3 and FT4 levels are normal, patients can be included); Bilirubin ≤1.5×ULN; ALT and AST ≤3×ULN; Alkaline phosphatase (AKP) ≤2.5×ULN; Serum creatinine ≤1.5×ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify